Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
Authors
Keywords
-
Journal
PLoS One
Volume 7, Issue 7, Pages e41347
Publisher
Public Library of Science (PLoS)
Online
2012-07-25
DOI
10.1371/journal.pone.0041347
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer
- (2011) Leticia De Mattos-Arruda et al. Clinical Colorectal Cancer
- Re: Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
- (2011) G. Brandi et al. JNCI-Journal of the National Cancer Institute
- Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
- (2011) Jeeyun Lee et al. JNCI-Journal of the National Cancer Institute
- Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
- (2010) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis
- (2010) Takeshi Seta et al. GASTROINTESTINAL ENDOSCOPY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
- (2009) Nicola Normanno et al. Nature Reviews Clinical Oncology
- High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal Cancer
- (2008) Lisa Simi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started